

## IN THE CLAIMS

1. (Previously Presented) A method of treating a cognitive memory dysfunction in a mammal, said method comprising administering to said mammal a pharmaceutically acceptable composition consisting essentially of a memory enhancing effective amount of *gugulipid*,

wherein said *gugulipid* is prepared by a method comprising extracting a resin from the aerial branches of the plant *C. wightii* and said resin is extracted by a process comprising:

- a) suspending a gum or resin of the plant in a non-polar solvent;
- b) filtering or decanting the soluble portion;
- c) extracting a fatty acid;
- d) extracting the residue with ethyl acetate using shaking or sonication;
- e) mixing the polar and non-polar fractions;
- f) filtering to remove the solid suspension; and
- g) removing the solvent to obtain the *gugulipid*.

2. (Previously Presented) The method of Claim 1, wherein said *gugulipid* is administered in the form of extracts, solid dosages or cream formulations.

3. (Previously Presented) The method of Claim 1, wherein said *gugulipid* is administered as an extract alone or admixed with a pharmaceutically acceptable additive.

4. (Previously Presented) The method of Claim 1, wherein said additive is selected from the group consisting of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, microcrystalline cellulose, starch, calcium carbonate and pharmaceutically acceptable carriers.

5. (Currently Amended) The method of Claim 2, wherein the solid dosage is obtained by maceration of the ~~compound~~ *gugulipid*, starch and microcrystalline cellulose in proportions that provide a flowable powder.

6. (Currently Amended) The method of Claim 2, wherein the solid dosage in the form of tablet is obtained by dissolving *gugulipid* with ethanol solvent and adding starch and microcrystalline cellulose, evaporating the solvent, passing the material through 40 mesh size sieve to get the granules and compressing the granules to obtain tablets[[,]].

7. (Previously Presented) The method of Claim 1, wherein the *gugulipid* is used for treating patients suffering from human memory dysfunctions caused by Alzheimer's disease or Korsakoff's disease, alone or in combination with other treatments.

8. (Previously Presented) The method of Claim 1, wherein said dysfunction is an anticholinergic-induced amnesia.

9. (Previously Presented) The method of Claim 8, wherein the *gugulipid* is administered at a dosage level equivalent to 40 mg/kg/day for 7 days.

10. (Previously Presented) The method of Claim 8, wherein the *gugulipid* is administered as extract or solid dosage.

11. (Currently Amended) The method of Claim 8, wherein [[the]] a solid dosage is obtained by maceration of the ~~compound~~ *gugulipid*, starch and microcrystalline cellulose in proportions that provide a flowable powder.

12. (Currently Amended) The method of Claim 8, wherein [[the]] a solid dosage in the form of a tablet is obtained by dissolving *gugulipid* with ethanol and adding starch and microcrystalline cellulose, evaporating the solvent, passing the material through 40 mesh size sieve to ~~get the~~ obtain granules and compressing the granules to obtain tablets.

Claims 13 -29 (Canceled).